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Background: Traditionally, outpatient visits for COPD are fixed, pre-planned by the pulmonol-
ogist. This is not a patient centered method, nor, in times of increasing COPD prevalence and
resource constraints, perhaps the optimal method.
Objectives: This pilot study, determined the effect of an on-demand-system, patient initiated
outpatient visits, on health status, COPD-related healthcare resource-use and costs.
Methods: Patients were randomized between on-demand-system (n Z 49) and usual care
(n Z 51), with a 2-year follow-up. Primary, health status was assessed with Clinical COPD
Questionnaire (CCQ). Secondary endpoints were: St. George’s Respiratory Questionnaire
(SGRQ), Short Form-36 (SF-36) scores, visits to general practitioners (GP), pulmonologists,
and pulmonary nurse practitioners (PNP), exacerbations and total treatment costs from
healthcare providers and healthcare insurance perspectives.
Results: Participants had a mean FEV1 1.3  0.4 liters and were 69  9 years. CCQ total scores
deteriorated in both groups, with no significant difference between them. CCQ symptom
domain did show a significant and clinically relevant difference in favor of the on-demand-
group, 0.4  0.21, CI95% 0.87; 0.02, p Z 0.04.
Similar tendency was found for the SGRQ whereas results for SF-36 were inconsistent. Pa-
tients in the on-demand-group visited GP significantly less (p Z 0.01), but PNP significantly
more, p Z 0.003. Visits to pulmonologists and exacerbations were equally frequent in both
groups. Mean total costs per patient were lower in the on-demand-group in comparison withtment of Pulmonary Diseases, Dr. van Heesweg 2, 8025AB Zwolle, The Netherlands. Tel.: þ31 (0)38
la.nl (F.F. Berkhof), annehesselink@hotmail.com (A.M. Hesselink), d.l.c.vaessen@isala.nl (D.L.C.
.a.m.kerstjens@umcg.nl (H.A.M. Kerstjens), j.w.k.van.den.berg@isala.nl (J.W.K. van den Berg).
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1164 F.F. Berkhof et al.usual care, difference of V-518 (1993; 788) from healthcare provider and V-458 (2700;
1652) insurance perspective.
Conclusions: The on-demand-system was comparable with usual care, had a cost-saving ten-
dency, and can be instituted with confidence in the COPD outpatient care setting.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
major chronic diseases worldwide. Its prevalence is
increasing over time, putting pressure on outpatient clinics
[1e3]. Traditionally, outpatient visits are pre-planned by
the pulmonologist and often occur when patients are stable
and thus when little action is required. However, COPD has
varying unpredictable episodes of deteriorations and frank
acute exacerbations [2]. If urgent attention is needed, it is
frequently a struggle in the current system to respond to
this request because the outpatient clinic is fully booked.
Delay in treatment for an exacerbation COPD may result in
hospitalization or death [4], and lead to a deterioration of
health status [5]. While improving health status is precisely
an important goal in the treatment of patients with COPD
[6]. In the Netherlands, COPD-exacerbations account for
approximately 34% of the total respiratory-related health-
care costs [7].
Better adaptation to increasing demand on outpatient
clinics can be achieved by allowing patients to self-refer
when they consider an outpatient visit needed, a so called
on-demand-system, instead of fixed outpatient appoint-
ments initiated by pulmonologists [8]. This system might
reduce unnecessary outpatient visits and healthcare costs.
In the last years several studies [9e12] have investigated
the on-demand-system in patients with chronic inflamma-
tory diseases, i.e. inflammatory bowel disease (IBD) and
rheumatoid arthritis (RA). These studies compared on-
demand visits with rapid specialist access in times of
need with routinely booked appointments. One study [11]
in IBD patients reported that open access is preferred by
patients because the system increased the degree of con-
trol in their lives to make the decision of receiving medical
care. Two studies [10,12], 1 in IBD and 1 in RA patients,
showed fewer outpatient appointments in the open access
group. Both studies found no differences in health status
between the 2 groups, as measured with the Short Form-36
(SF-36). SF-36 is a generic health status questionnaire,
which allows comparison between different diseases,
though a disease-specific questionnaire could be of more
clinical value. No data exist on the effectiveness of an on-
demand-system to the outpatient clinic in patients with
COPD. Therefore we designed a pilot study to compare an
on-demand-system with routinely booked appointments.
Our primary hypothesis was that the on-demand-system
improves disease-specific health status in patients with
COPD after 24 months. Secondary hypotheses were that the
on-demand-system also leads to improvement of generic
health status, reduction of resource use in primary and
secondary care, and reduction of healthcare treatmentcosts from the healthcare provider’s and the healthcare
insurer’s perspective.
Materials and methods
Study design
This pilot study was a single-center prospective randomized
controlled trial, carried out in a large teaching hospital in
Zwolle, the Netherlands. Randomization was performed
with a computer minimization program [13] to achieve
balanced groups for: gender, age (<70 years or  70 years),
and predicted forced expiratory volume in 1 s (FEV1 < 40%
or 40%). Approval of the local ethics committee was
received (NL 14887.075.06, local number 07.0325). The
study was registered in Clinicaltrial.gov (NCT00556816).
Participants
Eligible patients were 40 years, COPD GOLD stage 2
(defined as post bronchodilator of FEV1 < 80% and a ratio of
FEV1 to forced vital capacity of <70%), smoking history >10
pack-years, and provided written informed consent.
Exclusion criteria were prior history of asthma; drugs or
alcohol abuse; incapability of completing questionnaires.
Interventions
On-demand group e Patients randomized to the on-demand
group had one fixed appointment a year. The patient
initiated other outpatient visits. Patients were instructed
to call the pulmonary NPs when they experienced an in-
crease of symptoms, like dyspnea, cough, sputum, hae-
moptysis or thoracic pain. The pulmonary NP followed the
on demand-protocol, specifically designed for this study, as
shown in the Supplement. If a patient contacted the pul-
monary NP, first a history was taken by phone to assess the
urgency. When according to the protocol the urgency was
low, an outpatient visit was planned the next day to the
pulmonary NP. When urgency was deemed, advice of a
pulmonologist was asked and an outpatient visit to the
pulmonologist was planned as soon as possible, preferably
within hours.
Control group e Patients in the control group continued
with traditional outpatient visits to the pulmonologist or
the pulmonary NP, initiated by the pulmonologist. The
frequency of visits was also left at the discretion of the
pulmonologist.
Procedures e At baseline post-bronchodilator spirom-
etry and smoking history were collected. At 6, 12, and 24
Randomized
n=100
t=0
CCQ n=44
SGRQ n=47
SF-36 n=46
CCQ n=42
SGRQ n=41
SF-36 n=41
CCQ n=41
SGRQ n=41
SF-36 n=39
CCQ n=45
SGRQ n=44
SF-36 n=43
On demand
n=49
HCRU 
n=49
Health 
status
Control
n=51
Health 
status
HCRU
N=51
CCQ n=42
SGRQ n=42
SF-36 n=40
CCQ n=36
SGRQ n=36
SF-36 n=36
CCQ n=37
SGRQ n=40
SF-36 n=40
CCQ n=37
SGRQ n=39
SF-36 n=38
t=6
t=24
t=12
Figure 1 Consort Flowchart. HCRU: Healthcare resource
use, CCQ: Clinical COPD Questionnaire, SGRQ: St. George’s
Respiratory Questionnaire, SF-36: Short-Form-36, t Z time in
months.
On-demand-system can be instituted for COPD 1165months, patients completed Clinical COPD Questionnaire
(CCQ) [14], St. George’s Respiratory Questionnaire (SGRQ)
[15] and SF-36 [16]. Questionnaires were sent to patients
and were returned by mail. At the end of the study GPs and
pharmacists were contacted to collect healthcare resource
use in primary care: GP visits and exacerbations. Hospital’s
computer system was used to collect healthcare resource
use in secondary care: visits to pulmonologists, pulmonary
NPs and exacerbations. An exacerbation was defined as a
sustained worsening of the patient’s condition, from stable
state and beyond normal day-to-day variations, that ne-
cessitates treatment with prednisolon, antibiotics or a
combination of both [17].
Endpoints
Primary endpoints were mean change in CCQ total and
domain scores (range from 0 to 6, with a lower score
signifying better health status, minimal clinical important
difference (MCID) of CCQ total score is 0.4) [18]. Secondary
endpoints were: SGRQ scores (range from 0 to 100, a low
score indicates a good health status, MCID of SGRQ total
score is 4) [19], SF-36 scores (range from 0 to 100, higher
scores represent better health status, MCID of SF-36 scores
is 4) [20], time to first exacerbation COPD, number of pa-
tients with at least one exacerbation COPD in primary and
secondary care, number of visits to pulmonologists and
pulmonary NPs, and number of GP visits for COPD.
Costs were calculated from two perspectives: health-
care provider and healthcare insurance. Direct healthcare
costs were determined retrospectively for a 2-year follow-
up period and included: visits to GPs, pulmonologists, pul-
monary NPs, number of visits to the emergency depart-
ment, number and length of hospital admissions.
The costs per unit for healthcare resource use variables
for the healthcare provider perspective were used from
Dutch manual for costing studies [21] and were transformed
from euros 2009 to euros 2013 using the consumer price
indexes from StatLine, electronic databank of Statistics
Netherlands. The costs per unit healthcare resource use for
the healthcare insurance perspective were extracted from
the Diagnosis Treatment Combination (DBC) of 2013 of our
hospital.
Analysis
Since this study was designed as a pilot study, sample size
was not determined.
Baseline characteristics were determined with descrip-
tive statistics. Analyses were done according to the
intention-to-treat-principle. Normal distributions were
checked using histograms. Differences between groups and
mean change scores after 24 months of CCQ, SGRQ and SF-
36 were tested using analysis of covariance (ANCOVA),
adjusting for baseline values [22]. Interaction terms be-
tween treatment group and baseline values were checked.
Repeated measurement analysis of variance (MANOVA) was
carried out in cases of whom complete CCQ total score data
on 6, 12 and 24 months were present. A log-rank test was
used to test differences in time to first exacerbation be-
tween study groups, which were graphically presented byKaplan-Meier-curves. Between-group comparisons of pro-
portions were performed using Chi-squared tests. Differ-
ences between groups in median values were tested using
the independent-samples median test.
Total costs were calculated as the sum of the healthcare
resource use costs per patient.
Bootstrapping of data was used to calculate the uncer-
tainty around the estimates of costs [23]. All statistical
analyses were performed on each of 1000 bootstrap repli-
cations and 95% confidence intervals (CI) were determined
for mean differences in costs were obtained by nonpara-
metric bootstrapping. P-values < 0.05 were considered
significant. Analyses were performed using SPSS-Statistics
version 19.0 (IBM corporation, Armonk, NY, USA).
Results
Participants
Recruitment started Oct. 10, 2007 and ended Oct.12, 2009,
the last patient finished after 24 months of follow-up. A
flowchart, Fig. 1, showed that 100 patients were random-
ized. Baseline characteristics were similar for both groups,
Table 1.
Primary outcome
Both groups showed an increase in CCQ total score after 24
months, indicating a decline in health status. CCQ symptom
domain showed a significantly smaller deterioration in
health status in favor of the on-demand-group, which also
met the MCID, Table 2.
Table 1 Patient characteristics.
On-demand (n Z 49) Control (n Z 51)
Age (years), mean (SD) 69  9 69  9
Male sex, n (%) 36 (73.5) 38 (74.5)
FEV1 (L), post bronchodilator, mean (SD) 1.25  0.43 1.33  0.46
FEV1 %predicted, post bronchodilator, mean (SD) 45.5  11.6 47.0  13.5
FEV1/FVC post bronchodilator, ratio (%), mean (SD) 40.7  10.0 40.8  11.3
BMI (kg/m2), mean (SD) 26.8  4.7 27.2  5.6
Pack-years, median (range) 40.0 (2e117) 39.5 (2e124)
CCQ scores, mean (SD)
Total 2.1  0.9 2.2  1.0
Symptoms 2.4  0.9 2.4  1.0
Functional state 2.3  1.3 2.5  1.3
Mental state 1.0  1.0 1.0  1.1
BMI Z body mass index; CCQZ Clinical COPD Questionnaire; FEV1 Z forced expiratory volume in the first second; FVC Z forced vital
capacity; SD Z standard deviation.
Pack-years was missing for one patient in the control group, n Z 50. For CCQ total and domain scores: On.
demand, n Z 44, Control, n Z 37.
Table 2 Change from baseline and differences at 24 months in CCQ.
CCQ On-demand (n) Control (n) Difference 95% CI p-Value
Total 0.33  0.11 (40) 0.53  0.13 (29) 0.20  0.17 0.55; 0.14 0.24
Symptoms 0.14  0.14 (40) 0.58  0.16 (29) 0.44  0.21 0.87; 0.023 0.04
Functional state 0.59  0.16 (40) 0.57  0.18 (29) 0.02  0.24 0.46; 0.50 0.93
Mental state 0.13  0.12 (40) 0.34  0.14 (29) 0.21  0.19 0.58; 0.17 0.28
CCQ Z Clinical COPD Questionnaire; CI Z Confidence Interval.
All scores are presented as mean with standard error and were adjusted for baseline.
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Similar to the CCQ, the SGRQ also deteriorated in both
groups, Table 3. Difference in the SGRQ symptom domain
showed a smaller deterioration, in favor of the on-demand-
group and met the MCID.
There were no statistically significant differences be-
tween both groups in any of the SF-36 domains over 2 years,
Table 3. Nevertheless, some domains showed differences
between the groups that reached the MCID but were too
variable to be significant: bodily pain, role emotional, and
mental health.
The time path of deterioration in health status was
comparable in both groups during the 2 years follow-up for
the CCQ (pZ 0.86), SGRQ (pZ 0.81) and SF-36 (pZ 0.88),
as depicted in Fig. 2.
The GP was visited significantly less frequently for COPD
in the on-demand-group (p Z 0.01), as illustrated in Table
4. The percentage of patients in the on-demand-group that
had no visit to the GP for COPD in the 2 years was 20.4% in
comparison with 13.7% in the control group (p Z 0.37). In
the on-demand-group 57.1% of the patients had an exac-
erbation treated by the GP in comparison with 64.7% in the
control group in 2 years, p Z 0.23. In secondary care the
number of patients with at least one exacerbation were
comparable for the on-demand-group and the control
group, 19 (38.8%) versus 16 (31.4%) respectively (pZ 0.44).
The number of visits to the pulmonary NP increased
significantly in the on-demand compared to the controlgroup, p Z 0.003. Visits to the pulmonologist, exacerba-
tions and hospitalizations were similar in both groups.
The median time to the first exacerbation COPD, in both
primary and secondary care, was 307  61.6 days (95%CI
186.3; 427.7) in the on-demand-group compared with
335  60.2 days (95%CI 217.0; 453.0) in the control group
(p Z 0.40 log-rank test), Fig. 3. The total number of ex-
acerbations, treated either by GP or in the hospital, was
very similar in both groups (47 in the on-demand-group
versus 49 in the control group).
Healthcare resource use and costs are presented in
Table 5. Total costs were lower in the on-demand-group in
comparison with the control group both from the health-
care provider and healthcare insurance perspective,
although this did not reach statistical significance. The
mean savings were V518 (95%CI 1993; 788) and V458 (95%
CI 2700; 1652) per patient respectively. As expected, the
costs of the pulmonary NP were significantly higher in the
on-demand-group for both perspectives.Discussion
This pilot study evaluated the effect of an on-demand-
system outpatient-scheduling scheme in patients with
COPD on health status and resource use of primary and
secondary care. In both groups health status deteriorated
over 2 years. Deterioration in disease-specific health status
total and domain scores was invariably smaller in the on-
Table 3 Change from baseline and differences at 24 months in SGRQ and SF-36.
SGRQ On-demand (n) Control (n) Difference 95% CI p-Value
Total score 5.0  2.2 (38) 6.4  2.4 (30) 1.4  3.3 7.9; 5.1 0.67
Symptoms 2.6  3.0 (38) 10.3  3.4 (30) 7.7  4.6 16.8; 1.4 0.10
Activity 4.2  2.5 (38) 2.8  2.8 (30) 1.4  0.7 6.1; 8.8 0.72
Impact 6.6  2.7 (38) 6.6  3.0 (30) 0.0  4.1 8.1; 8.2 0.99
SF-36 On-demand (n) Control (n) Difference 95% CI p-Value
General health 5.2  2.1 (37) 4.8  2.3 (30) 0.4  3.1 6.7; 5.8 0.89
Physical functioning 7.5  2.4 (38) 6.1  2.7 (29) 1.4  3.6 8.7; 5.7 0.68
Bodily pain 1.8  3.3 (38) 2.9  3.8 (29) 4.7  5.0 14.6; 5.3 0.36
Vitality 3.2  2.3 (38) 4.3  2.6 (30) 1.1  3.5 6.0; 8.2 0.75
Role physical 4.8  5.6 (35) 6.8  6.4 (27) 2.0  8.5 15; 19 0.81
Role emotional 2.0  6.9 (34) 13.6  7.8 (27) 11.6  0.3 9.2; 32.4 0.27
Social functioning 7.1  3.3 (39) 7.5  3.7 (30) 0.4  5.0 9.6; 10.4 0.94
Mental health 0.3  2.4 (38) 4.4  2.7 (30) 4.1  3.6 3.1; 11.4 0.26
CI Z Confidence Interval; SGRQ Z St. George’s Respiratory Questionnaire; SF-36 Z Short Form-36.
All scores are presented as mean with standard error and were adjusted for baseline values.
On-demand-system can be instituted for COPD 1167demand-group, but the differences were not significant.
The exception was the symptom domain of both CCQ and
SGRQ, showing significant and borderline significant mean
differences over 2 years, respectively, in favor of the on-
demand-group. These mean differences also met the MCID
[18,19], indicating a clinically relevant effect.
Statistically significantly fewer patients with COPD in
the on-demand-group visited the GP in comparison with the
control group. In secondary care number of visits to pul-
monologists was similar in both groups, while number of
visits to the pulmonary NP significantly increased in the on-1.5
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Table 4 Resource use in primary and secondary care over 2 years.
On-demand (n Z 49) Control (n Z 51) p-Value
Primary care
Visits GP 4 (0e32) 5 (0e20) 0.01
Exacerbations 0 (0e4) 0 (0e4) 0.32
Secondary care
Outpatient visits
Total 4 (1e22) 4 (0e13) 0.97
Pulmonologist 3 (0e17) 3 (0e13) 0.82
Pulmonary NP 1 (0e14) 0 (0e4) 0.003
Exacerbations 1 (0e15) 2 (0e8) 0.57
Hospital days 0 (0e24) 0 (0e36) 0.73
GP Z general practitioner (n Z 48 in the On-demand group); Pulmonary NP Z Pulmonary nurse practitioner.
All scores are presented as median with range. P-value is calculated with the independent-samples median test. Exacerbations: median
number of patients with at least one exacerbation COPD.
1168 F.F. Berkhof et al.visits could lead to inadvertent health status loss, this
should be tested in a next study.
An explanation of the clinically relevant difference in
the symptom domain scores of CCQ and SGRQ in favor of the
on-demand-group could be that patients in the on-demand-
group were more in control. If patients with COPD experi-
ence increasing symptoms, which is a stressful situation,
they try to reduce or tolerate this with cognitive and
behavioral efforts [24]. In the on-demand-group they could
directly contact the pulmonary NP when needed. In this
way patients were allowed to talk about their complaints
and worries, and therefore ensure efforts to manage this
situation. This could also have positively affected mental
health which is supported by our findings of the mean dif-
ference in favor of the on demand group in the SF-36 do-
mains role emotional and mental health.
Worsening symptoms of patients with COPD were
noticed earlier. Probably, that was the reason that the
median number of days to the first exacerbation COPD wasFigure 3 Time to first exacerbation COPD. Kaplan Meier
curves showing the proportion of patients with at least one
exacerbation COPD, in primary and secondary care, against
time in days in the on-demand and the control group.slightly shorter in the on-demand-group. Many studies of
self-management of COPD have found higher total numbers
of exacerbations in the self-management group, but usually
of the milder sort and accompanied by beneficial effects on
other parameters [25,26]. Costs of severe exacerbations
were 7 times as high as milder exacerbations; these costs
were almost entirely (for 86%), due to hospitalized days [7].
The on-demand group showed a cost-saving trend from
both the healthcare provider and the healthcare insurance
perspective, in comparison with the control group. The
reduction in total costs for both perspectives was not signifi-
cant, however this pilot study was not designed for cost-
analysis.
Recent studies [9e12] compared the on-demand system
in other diseases, i.e. RA or IBD, but not COPD. Two studies
[10,12] used SF-36 to assess health status. In both studies no
significant difference was found between the groups, similar
to our study. One study [12] had resource use of primary and
secondary care as endpoint and therefore was comparable
with our study. Unlike our study, the on-demand-group
showed significantly fewer outpatient visits in comparison
to the control group, 4.12  3.41 versus 4.64  2.38
respectively (p Z 0.002). However, during follow-up pa-
tients were transferred back to GP and had no routine ap-
pointments in the hospital anymore. Specialists were only
contacted when rapid access was needed. In our study pa-
tients in the on-demand-group were seen in secondary care
once a year per protocol and medical care was not trans-
ferred back to GPs. Patients could contact the pulmonary NP
by phone if medical care was deemed necessary. Probably
this explains the different findings regarding resource use of
secondary care between the studies.
A recent study [27] evaluated the cooperation between
pulmonary NP and general practitioner for COPD patients in
primary care. In this study, disease specific health status
showed no significant or clinically relevant difference but
an improvement was seen in quality of care and patient
knowledge of COPD. A small study [28] of chronic illness,
i.e. COPD, led by the pulmonary NP in secondary care
showed that patients preferred this care above the usual
care. No randomized controlled trials have been published
yet evaluating cooperation of the pulmonary nurse and the
pulmonologist in the outpatient clinic. Probably, manage-
ment of patients with COPD with minor symptoms by the
Table 5 Treatment costs per patient (in euros, 2013).
Unit costs On-demand
(n Z 49)
Control
(n Z 51)
Difference V
Healthcare provider Euros 2013
Outpatient visits GP 30.00 139 (193) 173 (148) 34 (96; 37)
Pulmonologist 68.00 257 (203) 270 (182) 13 (85; 67)
Pulmonary NP 37.00 53 (86) 20 (38) 33 (10; 62)
Inpatient visits Emergency room 161.00 82 (124) 108 (190) 26 (89; 37)
Pulmonary ward, per day 465.00 1272 (2342) 1750 (3722) 478 (1857; 742)
Total costs healthcare provider 1803 (2617) 2321 (3967) 518 (1993; 788)
Healthcare insurance Tariff 2013
Outpatient visits GP 8.78 41 (57) 51 (43) 10 (30; 12)
Pulmonologist 274.55 1031 (813) 1082 (729) 51 (362; 240)
Pulmonary NP 274.55 387 (634) 145 (282) 242 (59; 437)
Inpatient visits Emergency room 1865.53 952 (1431) 1244 (2197) 292 (1076; 435)
Pulmonary ward Reimbursement 1583 (2788) 1930 (3741) 347 (1731; 986)
Total costs healthcare insurance 3994 (4669) 4452 (6100) 458 (2700; 1652)
GP Z General practitioner (n Z 48 in the On-demand group), Pulmonary NP Z Pulmonary Nurse practitioner.
Data are presented as mean (standard deviation).
Reimbursements in the Netherlands are categorized, based on the number of hospitalization days: 1e4 days: V1865.53, 5e14 days:
V3890.80, 15e28 days: V8183.31.
On-demand-system can be instituted for COPD 1169pulmonary NP instead of the pulmonologist could also
reduce healthcare costs.
One limitation was the design of a pilot study. We choose
for a pilot study because the on-demand-system had not
been investigated in patients with COPD before. Results of
this study are therefore exploratory and give the opportunity
for future studies to compute proper sample sizes. Another
limitation was the missing data at baseline and the loss to
follow-up in the control group to assess health status. The
last limitation is that 2 patients did not meet the inclusion
criteria of smoking history of >10 pack-years. However, a
proportion of patients with COPD never smoked [29].
Conclusions
In conclusion, this study found that the on-demand-system
is comparable in terms of health status and resource use in
primary and secondary care, with fixed outpatient visits
pre-planned by the pulmonologist and therefore applicable
in patients with COPD. A cost-saving tendency was found in
favor of the on-demand-group from both healthcare pro-
vider and healthcare insurance perspective. Interestingly,
the tendency for cost-savings for the on-demand-system in
secondary care was not reached by increasing pressure on
primary care: it even reduced the burden of COPD in pri-
mary care. We suggest that an on-demand-system by pa-
tients with COPD is safe and could convey advantages in
health status, perhaps increasing self-efficacy skills, this
needs to be tested in a larger randomized controlled trial
for which power calculations can now be made. Addition-
ally, cost-effectiveness can then be studied in more detail.
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